IMAGING TUMOR VARIATION IN RESPONSE TO PHOTODYNAMIC THERAPY IN PANCREATIC CANCER XENOGRAFT MODELS

被引:46
|
作者
Samkoe, Kimberley S. [1 ]
Chen, Alina [1 ]
Rizvi, Imran [1 ,2 ]
O'Hara, Julia A. [1 ]
Hoopes, P. Jack [1 ,3 ]
Pereira, Stephen P. [4 ]
Hasan, Tayyaba [2 ]
Pogue, Brian W. [1 ,2 ,3 ]
机构
[1] Dartmouth Coll, Thayer Sch Engn, Hanover, NH 03766 USA
[2] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA
[3] Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Dept Surg, Hanover, NH 03756 USA
[4] UCL, Sch Med, Inst Hepatol, London W1N 8AA, England
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2010年 / 76卷 / 01期
基金
美国国家卫生研究院;
关键词
Photodynamic therapy; Pancreatic cancer; Magnetic resonance imaging; Tumor aggressiveness; Orthotopic tumor; ENDOTHELIAL GROWTH-FACTOR; VERTEPORFIN; ADENOCARCINOMA; GEMCITABINE;
D O I
10.1016/j.ijrobp.2009.08.041
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: A treatment monitoring study investigated the differential effects of orthotopic pancreatic cancer models in response to interstitial photodynamic therapy (PDT), and the validity of using magnetic resonance imaging as a surrogate measure of response was assessed. Methods and Materials: Different orthotopic pancreatic cancer xenograft models (AsPC-1 and Panc-1) were used to represent the range of pathophysiology observed in human beings. Identical dose escalation studies (10, 20, and 40J/cm) using interstitial verteporfin PDT were performed, and magnetic resonance imaging with T2-weighted and T1-weighted contrast were used to monitor the total tumor volume and the vascular perfusion volume, respectively. Results: There was a significant amount of necrosis in the slower-growing Panc-1 tumor using high light dose, although complete necrosis was not observed. Lower doses were required for the same level of tumor kill in the faster-growing AsPC-1 cell line. Conclusions: The tumor growth rate and vascular pattern of the tumor affect the optimal PDT treatment regimen, with faster-growing tumors being relatively easier to treat. This highlights the fact that therapy in human beings shows a heterogeneous range of outcomes, and suggests a need for careful individualized treatment outcomes assessment in clinical work. (C) 2010 Elsevier Inc.
引用
收藏
页码:251 / 259
页数:9
相关论文
共 50 条
  • [41] A Theranostic Nanoprobe for Hypoxia Imaging and Photodynamic Tumor Therapy
    Fan, Jing Hao
    Fan, Gui Ling
    Yuan, Ping
    Deng, Fu An
    Liu, Ling Shan
    Zhou, Xiang
    Yu, Xi Yong
    Cheng, Hong
    Li, Shi Ying
    FRONTIERS IN CHEMISTRY, 2019, 7
  • [42] Photodynamic therapy enables tumor-specific ablation in preclinical models of thyroid cancer
    Muhanna, Nidal
    Chan, Harley H. L.
    Townson, Jason L.
    Jin, Cheng S.
    Ding, Lili
    Valic, Michael S.
    Douglas, Catriona M.
    MacLaughlin, Christina M.
    Chen, Juan
    Zheng, Gang
    Irish, Jonathan C.
    ENDOCRINE-RELATED CANCER, 2020, 27 (02) : 41 - 53
  • [43] Pathologic tumor response to neoadjuvant therapy in borderline resectable pancreatic cancer
    June S Peng
    Jane Wey
    Sricharan Chalikonda
    Daniela S Allende
    R Matthew Walsh
    Gareth Morris-Stiff
    Hepatobiliary & Pancreatic Diseases International, 2019, 18 (04) : 373 - 378
  • [44] A Liposomal Gemcitabine, FF-10832, Improves Plasma Stability, Tumor Targeting, and Antitumor Efficacy of Gemcitabine in Pancreatic Cancer Xenograft Models
    Takeshi Matsumoto
    Takashi Komori
    Yuta Yoshino
    Tadaaki Ioroi
    Tsukasa Kitahashi
    Hiromu Kitahara
    Kohei Ono
    Tamami Higuchi
    Masayo Sakabe
    Hiroshi Kori
    Masahiro Kano
    Ritsuko Hori
    Yukio Kato
    Shinji Hagiwara
    Pharmaceutical Research, 2021, 38 : 1093 - 1106
  • [45] Perspectives on the Role of Photodynamic Therapy in the Treatment of Pancreatic Cancer
    Li, Wei
    Ma, Qingyong
    Wu, Erxi
    INTERNATIONAL JOURNAL OF PHOTOENERGY, 2012, 2012
  • [46] Magnetic Resonance Imaging Monitors Physiological Changes With Antihedgehog Therapy in Pancreatic Adenocarcinoma Xenograft Model
    Guimaraes, Alexander R.
    Rakhlin, Elena
    Weissleder, Ralph
    Thayer, Sarah P.
    PANCREAS, 2008, 37 (04) : 440 - 444
  • [47] A Liposomal Gemcitabine, FF-10832, Improves Plasma Stability, Tumor Targeting, and Antitumor Efficacy of Gemcitabine in Pancreatic Cancer Xenograft Models
    Matsumoto, Takeshi
    Komori, Takashi
    Yoshino, Yuta
    Ioroi, Tadaaki
    Kitahashi, Tsukasa
    Kitahara, Hiromu
    Ono, Kohei
    Higuchi, Tamami
    Sakabe, Masayo
    Kori, Hiroshi
    Kano, Masahiro
    Hori, Ritsuko
    Kato, Yukio
    Hagiwara, Shinji
    PHARMACEUTICAL RESEARCH, 2021, 38 (06) : 1093 - 1106
  • [48] CT contrast predicts pancreatic cancer treatment response to verteporfin-based photodynamic therapy
    Jermyn, Michael
    Davis, Scott C.
    Dehghani, Hamid
    Huggett, Matthew T.
    Hasan, Tayyaba
    Pereira, Stephen P.
    Bown, Stephen G.
    Pogue, Brian W.
    PHYSICS IN MEDICINE AND BIOLOGY, 2014, 59 (08) : 1911 - 1921
  • [50] Synergetic anticancer effect of combined gemcitabine and photodynamic therapy on pancreatic cancer in vivo
    Xie, Qi
    Lia, Lin
    Liu, Yan-Hong
    Wei, Cheng-Gang
    WORLD JOURNAL OF GASTROENTEROLOGY, 2009, 15 (06) : 737 - 741